Targeting a specific gene to improve treatment for advanced ovarian cancer
Project 2: Targeting CCNE1 overexpression in high grade serous ovarian cancer
['FUNDING_OTHER'] · JOHNS HOPKINS UNIVERSITY · NIH-10935407
This study is looking at a new drug called ZN-c3 to see if it can help people with high-grade serous ovarian cancer by targeting a specific gene that often causes the cancer to grow faster, and it aims to find out which patients might get the most benefit from this treatment.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | JOHNS HOPKINS UNIVERSITY (nih funded) |
| Locations | 1 site (BALTIMORE, UNITED STATES) |
| Trial ID | NIH-10935407 on ClinicalTrials.gov |
What this research studies
This research focuses on high-grade serous ovarian cancer (HGSC) and aims to improve treatment outcomes by targeting the CCNE1 gene, which is often overexpressed in patients with this type of cancer. The study investigates the effectiveness of a new drug, ZN-c3, which inhibits the WEE1 kinase, a key regulator of cell cycle progression. By analyzing tumor samples and identifying biomarkers, the research seeks to determine which patients are most likely to benefit from this treatment. The approach builds on previous findings that combining therapies can overcome resistance to existing treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with high-grade serous ovarian cancer who exhibit CCNE1 overexpression.
Not a fit: Patients with other types of ovarian cancer or those without CCNE1 overexpression may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide new therapeutic options for patients with advanced ovarian cancer who currently have limited treatment choices.
How similar studies have performed: Previous research has shown promising results with similar approaches targeting genomic alterations in ovarian cancer, indicating a potential for success in this novel treatment strategy.
Where this research is happening
BALTIMORE, UNITED STATES
- JOHNS HOPKINS UNIVERSITY — BALTIMORE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SIMPKINS, FIONA — JOHNS HOPKINS UNIVERSITY
- Study coordinator: SIMPKINS, FIONA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancer Patient